1-3 of 3
Xavier Parot
Close
Sort by
Journal Articles

Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don M. Benson, Jr., Kaveri Suryanarayan, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman
Journal: Blood
Blood (2022) 140 (Supplement 1): 1357–1359.
https://doi.org/10.1182/blood-2022-162253
Published: 2022
Journal Articles

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

Dan T. Vogl, Jonathan L. Kaufman, Sarah A. Holstein, Shebli Atrash, Omar Nadeem, Murali Janakiram, Kaveri Suryanarayan, Yuyin Liu, Sabrina Collins, Xavier Parot, Maria Chaudhry
Journal: Blood
Blood (2021) 138 (Supplement 1): 898.
https://doi.org/10.1182/blood-2021-148463
Published: 2021
Journal Articles

TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma

Dan T. Vogl, MD, Jonathan L. Kaufman, MD, Sara A. Holstein, MDPhD, Omar Nadeem, MD, Elizabeth O'Donnell, MD, Kaveri Suryanarayan, MD, Sabrina Collins, Xavier Parot, MD, Maria Chaudhry, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-141219
Published: 2020